EUCTR2012-000394-23-PT进行中（未招募）不适用
A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer - SOLTI NEOERIBULI
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- SOLTI
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written IC must be given according to ICH/GCP guidelines and national/local regulations before patient registration, specifically highlighting the generation of molecular characterization of tumor and genomic samples. 2.Age ?18 years. 3.Histologically confirmed invasive breast carcinoma with all of the following characteristics: a.Primary tumor ?2 cm in largest diameter (cT1-3) assessed by physical examination and mammography and/or breast US and/or breast MRI (where available). If the tumor is not palpable or measures less than 2 cm in physical examination, the patient is eligible if the imaging technique (mammography and/or breast US and/or breast MRI) shows a tumor of at least 2 cm. b.cN0-1: patients with clinically evident axillary lymph nodes can be included, but not if metastasis in ipsilateral level I/II axillary lymph nodes are fixed to one another (matted) or to other structures (N2a). Patients with clinically involved internal mammary or supraclavicular nodes (i.e., cN2b-3) are also excluded. c.No evidence of distant metastasis (M0). 4.BC must be eligible for definitive primary surgery. 5.Available pre-treatment core (Tru-cut) biopsy or possibility of performing one. 6.HER2- BC (as per local assessment), defined by any of the following: a.0-1+ expression by IHC. b.2+ expression by IHC and in situ hybridization (FISH/CISH) without HER2 gene amplification (<4 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to Cr17 signals] of <1.8). c.Is situ hybridization (FISH/CISH) without HER2 gene amplification, independently of IHC. 7.Known hormone receptor (ER/PgR) status (as per local assessment) or possibility of performing the tests. 8.Known percentage of hormone receptor (ER/PgR) and Ki67-positive tumor cells (as per local assessment), or possibility of performing the tests. 9.Multifocal tumors (defined as the presence of two or more foci of cancer within the same breast quadrant) are allowed. However, if a multifocal tumor is present: a.The largest lesion must be ?2 cm. It will be considered as the target lesion for all subsequent tumor evaluations. b.HER2- status must be documented in all the tumor foci. c.ER/PgR status of the target lesion will be considered to classify the BC subtype, as determined by IHC criteria. 10.ECOG performance status of 0 or 1 11.Adequate laboratory values as follows: a.Absolute neutrophil count (ANC) ?1.5 x 109/L. b.Platelets count ?100 x 109/L. c.Hemoglobin ?9 g/dL. d.Serum bilirubin ?1.5 time the upper limit of normal (ULN). In the case of known Gilbert?s syndrome, a higher serum total bilirubin (<2 x ULN) is allowed. e.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x ULN. f.Alkaline phosphatase (AP) ?2.5 x ULN. g.Serum creatinine ?1.5 mg/dL or calculated creatinine clearance ?60 mL/m. 12.Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. 13.Ability and willingness to comply with study visits, treatment, testing, and to comply with the protocol; those conditions should be discussed with the patient before registration in the trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Any prior treatment for primary invasive BC. 2.Metastatic, locally advanced, or inflammatory BC (i.e., Stage III or IV BC). 3.Bilateral invasive BC. 4.Multicentric BC, defined as the presence of two or more foci of cancer in different quadrants of the same breast. 5.Pre-existing peripheral neuropathy of any grade. 6.Uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100mmHg). 7.Clinically significant (i.e., active) cardiovascular disease, including cerebrovascular accident (?6 months before enrolment), myocardial infarction (?6 months before enrolment), unstable angina, New York Heart Association ? grade 2 congestive heart failure, serious cardiac arrhythmia requiring medication during the study and that might interfere with regularity of the study treatment, or not controlled by medication. 8.Long QT syndrome. 9.Concomitant use of inhibitors of hepatic transport proteins, such as organic anion-transporting proteins (OATPs), P-glycoprotein (Pgp), multidrug resistant proteins (MRPs), etc. Inhibitors of such transporters include but are not limited to: cyclosporine, ritonavir, saquinavir, lopinavir, and certain other protease inhibitors, efavirenz, emtricitabine, verapamil, clarithromycin, quinine, quinidine and disopyramide. 10.Major medical conditions that might affect study participation (e.g., active peptic ulcer disease, uncontrolled diabetes mellitus, uncontrolled seizure disorder, uncontrolled pulmonary, renal or hepatic dysfunction, or uncontrolled infection). 11.Other primary malignant tumors within the previous 5 years, except for adequately controlled limited basal cell carcinoma of the skin or carcinoma in situ of the cervix. 12.Known human immunodeficiency virus (HIV) infection or other active or serious infection requiring IV antibiotics at randomizationenrollment. 13.Pregnancy or breastfeeding women. 14.Women of childbearing potential (<2 years after the last menstruation) not using effective, non-hormonal means of contraception (e.g., intra-uterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly, or surgically sterilized) during the study and for a period of 6 months following the last administration of study drug. 15.Administration of any live virus vaccine within 8 weeks preceding study entry. 16.Use of any investigational agent within 30 days of administration of the first dose of study drug or concurrent treatment on another clinical study. 17.Requirement for radiation therapy concurrent with study anticancer treatment. Patients who require breast or chest wall radiation therapy after surgery are eligible. 18.Known hypersensitivity to any of the study drugs or excipients. 19.Inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator or designee.
研究者
相似试验
进行中（未招募）
不适用
A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancerEUCTR2012-000394-23-DESOLTI200
进行中（未招募）
不适用
A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancerEUCTR2012-000394-23-ESSOLTI200
进行中（未招募）
不适用
An exploratory study to assess the efficacy using imaging of oral enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with androgen deprivation.Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation TherapyMedDRA version: 18.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001162-10-NLEuropean Uro- Oncology Group (EUOG)60
进行中（未招募）
不适用
An exploratory study to assess the efficacy using imaging of oral Enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with anti-androgens.Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients)MedDRA version: 18.0Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001161-27-NLEuropean Uro- Oncology Group (EUOG)60
已完成
2 期
An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients)10027476metastatic prostate cancerNL-OMON45038eids Universitair Medisch Centrum60